120 related articles for article (PubMed ID: 12736050)
1. Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma.
Miyajima A; Asano T; Seta K; Asano T; Kakoi N; Hayakawa M
Urology; 2003 May; 61(5):1072-7. PubMed ID: 12736050
[TBL] [Abstract][Full Text] [Related]
2. Reduction of transforming growth factor-beta type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma.
Fukasawa H; Yamamoto T; Fujigaki Y; Misaki T; Ohashi N; Takayama T; Suzuki S; Mugiya S; Oda T; Uchida C; Kitagawa K; Hattori T; Hayashi H; Ozono S; Kitagawa M; Hishida A
Int J Cancer; 2010 Oct; 127(7):1517-25. PubMed ID: 20073064
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients.
Tokunaga H; Lee DH; Kim IY; Wheeler TM; Lerner SP
Clin Cancer Res; 1999 Sep; 5(9):2520-5. PubMed ID: 10499628
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
[TBL] [Abstract][Full Text] [Related]
5. Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma.
Furue M; Kato M; Nakamura K; Nashiro K; Kikuchi K; Okochi H; Miyazono K; Tamaki K
Int J Cancer; 1997 May; 71(4):505-9. PubMed ID: 9178800
[TBL] [Abstract][Full Text] [Related]
6. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta type II receptor confers tumor suppressor activity in murine renal carcinoma (Renca) cells.
Engel JD; Kundu SD; Yang T; Lang S; Goodwin S; Janulis L; Cho JS; Chang J; Kim SJ; Lee C
Urology; 1999 Jul; 54(1):164-70. PubMed ID: 10414746
[TBL] [Abstract][Full Text] [Related]
8. [Detection of the expression of Smad4, transforming growth factor beta(1) and beta receptor II proteins in paraffin-embedded human pancreatic cancer tissues].
Gu L; Chen J; Liu T; Li L; Lu Z; Luo Y
Zhonghua Bing Li Xue Za Zhi; 2001 Dec; 30(6):439-42. PubMed ID: 11866987
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta receptors in verrucous and squamous cell carcinoma.
Anderson M; Muro-Cacho C; Cordero J; Livingston S; Muñoz-Antonia T
Arch Otolaryngol Head Neck Surg; 1999 Aug; 125(8):849-54. PubMed ID: 10448730
[TBL] [Abstract][Full Text] [Related]
10. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy.
Lau WK; Cheville JC; Blute ML; Weaver AL; Zincke H
Urology; 2002 Apr; 59(4):532-7. PubMed ID: 11927308
[TBL] [Abstract][Full Text] [Related]
11. IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells.
Rosendahl AH; Forsberg G
Kidney Int; 2006 Nov; 70(9):1584-90. PubMed ID: 16969385
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Paterson IC; Matthews JB; Huntley S; Robinson CM; Fahey M; Parkinson EK; Prime SS
J Pathol; 2001 Apr; 193(4):458-67. PubMed ID: 11276004
[TBL] [Abstract][Full Text] [Related]
13. Expression of transforming growth factor beta1 and its type II receptor in mouse colon tumors induced by azoxymethane.
Wang QS; Guda K; Papanikolaou A; Dong M; Rosenberg DW
Int J Oncol; 2000 Sep; 17(3):551-8. PubMed ID: 10938397
[TBL] [Abstract][Full Text] [Related]
14. Lack of expression of transforming growth factor-beta type II receptor associated with malignant progression in human salivary gland cell clones.
Azuma M; Yuki T; Tamatani T; Motegi K; Yoshida H; Sato M
Int J Cancer; 1996 Jun; 66(6):802-5. PubMed ID: 8647653
[TBL] [Abstract][Full Text] [Related]
15. Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma.
Bristow RE; Baldwin RL; Yamada SD; Korc M; Karlan BY
Cancer; 1999 Feb; 85(3):658-68. PubMed ID: 10091739
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of tumour multifocality in renal cell carcinoma.
Siracusano S; Novara G; Antonelli A; Artibani W; Bertini R; Carini M; Carmignani G; Ciciliato S; Cunico SC; Lampropoulou N; Longo N; Martorana G; Minervini A; Mirone V; Simeone C; Simonato A; Valotto C; Zattoni F; Ficarra V;
BJU Int; 2012 Dec; 110(11 Pt B):E443-8. PubMed ID: 22502873
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor family and renal cell carcinoma: expression and prognostic impact.
Hofmockel G; Riess S; Bassukas ID; Dämmrich J
Eur Urol; 1997; 31(4):478-84. PubMed ID: 9187911
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma.
Abou-Shady M; Baer HU; Friess H; Berberat P; Zimmermann A; Graber H; Gold LI; Korc M; Büchler MW
Am J Surg; 1999 Mar; 177(3):209-15. PubMed ID: 10219856
[TBL] [Abstract][Full Text] [Related]
19. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis.
Mizutani Y; Nakanishi H; Li YN; Matsubara H; Yamamoto K; Sato N; Shiraishi T; Nakamura T; Mikami K; Okihara K; Takaha N; Ukimura O; Kawauchi A; Nonomura N; Bonavida B; Miki T
Int J Oncol; 2007 Apr; 30(4):919-25. PubMed ID: 17332931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
